

Mirati Therapeutics, Inc.
Form 10-Q
November 12, 2013
[Table of Contents](#)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-35921

MIRATI THERAPEUTICS, INC.

Edgar Filing: Mirati Therapeutics, Inc. - Form 10-Q

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State of Incorporation)

46-2693615
(I.R.S. Employer

Identification No.)

9363 Towne Centre Drive, Suite 200
San Diego, California
(Address of Principal Executive Offices)

92121
(Zip Code)

(858) 332-3410

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Total shares of common stock outstanding as of the close of business on November 7, 2013:

Class	Number of Shares Outstanding
Common Stock, \$0.001 par value	13,261,862

Table of Contents

MIRATI THERAPEUTICS, INC.

FORM 10-Q

TABLE OF CONTENTS

<u>PART I. FINANCIAL INFORMATION</u>		3
<u>Item 1.</u>	<u>Condensed Consolidated Financial Statements (Unaudited)</u>	<u>3</u>
	<u>Condensed Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012</u>	<u>3</u>
	<u>Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2013 and 2012</u>	<u>4</u>
	<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2013 and 2012</u>	<u>5</u>
	<u>Notes to Condensed Consolidated Financial Statements</u>	<u>6</u>
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>14</u>
<u>Item 4.</u>	<u>Controls and Procedures</u>	<u>20</u>
<u>PART II. OTHER INFORMATION</u>		19
<u>Item 1A.</u>	<u>Risk Factors</u>	<u>20</u>
<u>Item 2</u>	<u>Unregistered Sale of Securities</u>	<u>40</u>
<u>Item 6.</u>	<u>Exhibits</u>	<u>42</u>
<u>SIGNATURES</u>		43

Table of Contents**PART I. FINANCIAL INFORMATION****ITEM 1. Financial Statements****MIRATI THERAPEUTICS, INC.****CONSOLIDATED BALANCE SHEETS**

(In thousands)

(Unaudited)

	September 30, 2013	December 31, 2012
ASSETS		
Current assets		
Cash and cash equivalents	\$ 7,616	\$ 18,403
Marketable securities	7,418	18,580
Restricted cash equivalents and marketable securities	291	302
Interest and other receivables	186	507
Other current assets	1,510	1,537
Total current assets	17,021	39,329
Security deposits	99	67
Restricted cash equivalents and marketable securities	80	72
Deferred costs	374	
Property and equipment, net	427	333
Total assets	\$ 18,001	\$ 39,801
LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)		
Current liabilities		
Accounts payable and accrued liabilities	6,555	5,272
Current portion of other liability	60	68
Share-based compensation liability	2,144	
Warrant liability	32,803	
Total current liabilities	41,562	5,340
Other liability		45
Total liabilities	41,562	5,385
Stockholders equity (deficit)		
Preferred stock, \$0.001 par value, 10,000,000 shares authorized; none issued and outstanding at both September 30, 2013 and December 31, 2012		
Common stock, \$0.001 par value; 100,000,000 authorized; 9,960,621 and 9,957,725 issued and outstanding at both September 30, 2013 and December 31, 2012	10	10
Warrants		11,153
Additional paid-in capital	154,069	154,224
Accumulated other comprehensive income	9,520	9,520

Edgar Filing: Mirati Therapeutics, Inc. - Form 10-Q

Accumulated deficit	(187,160)	(140,491)
Total stockholders equity (deficit)	(23,561)	34,416
Total liabilities and stockholders equity (deficit)	\$ 18,001	\$ 39,801

See accompanying notes

Table of Contents

MIRATI THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands except for share and per share amounts)

(Unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2013	2012	2013	2012
Expenses				
Research and development, net	\$ 5,492	\$ 4,249	\$ 15,477	\$ 10,105
General and administrative	3,710	1,717	8,616	4,019
Total operating expenses	9,202	5,966	24,093	14,124
Loss from operations	(9,202)	(5,966)	(24,093)	(14,124)
Other (expense) income, net	(20,141)	34	(17,418)	172
Loss before income taxes	(29,343)	(5,932)	(41,511)	(13,952)
Income tax expense	55	14	115	27
Net loss and comprehensive loss	\$ (29,398)	\$ (5,946)	\$ (41,626)	\$ (13,979)